LFSC
F/m Emerald Life Sciences Innovation ETF
Price Chart
Latest Quote
$44.14
+0.91 (+2.11%)
Current Price
| Previous Close | $43.23 |
| Open | $43.94 |
| Day High | $44.65 |
| Day Low | $43.84 |
| Volume | 974 |
Fund Information
| Net Assets | $105.06M |
| Expense Ratio | 0.54% |
| Category | Health |
| Fund Family | Emerald Mutual Fund Advisers Trust |
| Net Asset Value | $43.31 |
| Premium/Discount | 1.93% |
| Exchange | NGM |
📊 ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $40.06 |
| SMA50 | $38.85 |
| SMA200 | $35.43 |
| RSI | 78.50 |
| ATR | 0.8554 |
| Rel Volume | 0.27 |
Performance History
| Week | +8.33% |
| Month | +14.31% |
| Quarter | +28.99% |
| 6 Months | +12.72% |
| YTD | +21.87% |
| Year | +78.03% |
| 10 Years | +77.34% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $44.14 | 974 |
| 2026-06-24 | $43.29 | 1,300 |
| 2026-06-23 | $42.60 | 900 |
| 2026-06-22 | $42.38 | 2,200 |
| 2026-06-18 | $41.52 | 5,600 |
| 2026-06-17 | $40.74 | 1,500 |
| 2026-06-16 | $40.42 | 4,300 |
| 2026-06-15 | $40.64 | 3,500 |
| 2026-06-12 | $40.17 | 4,600 |
| 2026-06-11 | $39.72 | 2,800 |
| 2026-06-10 | $38.58 | 3,000 |
| 2026-06-09 | $39.06 | 3,300 |
| 2026-06-08 | $37.87 | 9,100 |
| 2026-06-05 | $37.89 | 9,100 |
| 2026-06-04 | $39.08 | 1,700 |
| 2026-06-03 | $38.02 | 1,400 |
| 2026-06-02 | $37.62 | 6,800 |
| 2026-06-01 | $38.62 | 6,000 |
| 2026-05-29 | $39.39 | 2,100 |
| 2026-05-28 | $39.43 | 900 |
| 2026-05-27 | $39.07 | 3,500 |
| 2026-05-26 | $38.61 | 1,500 |
About F/m Emerald Life Sciences Innovation ETF
The fund is an actively managed exchange-traded fund (“ETF”) and invests primarily in equity securities of life science companies selected by Emerald Mutual Fund Advisers Trust, the fund’s investment sub-adviser, under the supervision of the adviser. Under normal market conditions, the fund invests at least 80% of its net assets in equity securities issued by life science companies demonstrating innovation.
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.